

## Letermovir Liquid Formulation

Version 1.20      Revision Date: 30.09.2023      SDS Number: 66869-00021      Date of last issue: 04.04.2023  
Date of first issue: 27.02.2015

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Letermovir Liquid Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
117 16th Road  
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

##### Additional Labelling

EUH210      Safety data sheet available on request.

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**Letermovir Liquid Formulation**

Version 1.20      Revision Date: 30.09.2023      SDS Number: 66869-00021      Date of last issue: 04.04.2023  
Date of first issue: 27.02.2015

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Letermovir	917389-32-3	Repr. 2; H361d STOT RE 2; H373 (Liver, spleen, Blood)	>= 1 - < 3

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

None known.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.

## Letermovir Liquid Formulation

Version 1.20      Revision Date: 30.09.2023      SDS Number: 66869-00021      Date of last issue: 04.04.2023  
Date of first issue: 27.02.2015

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.

## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.   |
| Local/Total ventilation | : | Use only with adequate ventilation.   |
| Advice on safe handling | : | Do not breathe mist or vapours.<br>Do not swallow.<br>Avoid contact with eyes.<br>Avoid prolonged or repeated contact with skin.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  |
| Hygiene measures        | : | Take care to prevent spills, waste and minimize release to the environment.<br>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |   |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Gases                  |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

## Letermovir Liquid Formulation

Version 1.20      Revision Date: 30.09.2023      SDS Number: 66869-00021      Date of last issue: 04.04.2023  
 Date of first issue: 27.02.2015

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Letermovir	917389-32-3	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal

#### 8.2 Exposure controls

##### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

##### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Skin and body protection	:	Work uniform or laboratory coat.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Appearance	:	liquid
Colour	:	clear
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	7,5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available

**Letermovir Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Flammability (liquids)	:	No data available
Particle size	:	Not applicable

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

**10.4 Conditions to avoid**

Conditions to avoid	:	None known.
---------------------	---	-------------

**10.5 Incompatible materials**

## Letermovir Liquid Formulation

Version 1.20      Revision Date: 30.09.2023      SDS Number: 66869-00021      Date of last issue: 04.04.2023  
Date of first issue: 27.02.2015

---

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Letermovir:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
LD50 (Mouse): > 2.000 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Letermovir:

Remarks : No data available

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Letermovir:

Remarks : No data available

#### Respiratory or skin sensitisation

##### Skin sensitisation

Not classified based on available information.

##### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Letermovir:

Remarks : No data available

## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Letermovir:

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative
- Test Type: Chromosome aberration test in vitro  
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative
- Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### Letermovir:

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Application Route: Oral  
Fertility: NOAEL: 240 mg/kg body weight  
Result: No effects on fertility
- Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 180 mg/kg body weight  
Result: No effects on fertility  
Remarks: The significance of these findings for humans is not certain.
- Test Type: Fertility/early embryonic development  
Species: Monkey, male  
Application Route: Oral  
Fertility: NOAEL: 240 mg/kg body weight  
Result: No effects on fertility
- Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Developmental Toxicity: LOAEL: 250 mg/kg body weight  
Result: Embryo-foetal toxicity  
Remarks: Maternal toxicity observed.



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Developmental Toxicity: LOAEL: 225 mg/kg body weight  
 Result: Embryo-foetal toxicity, Malformations were observed.,  
 Abortion  
 Remarks: Maternal toxicity observed.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Components:

#### Letermovir:

Exposure routes : Ingestion  
 Target Organs : Liver, spleen, Blood  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Letermovir:

Species	: Mouse
NOAEL	: 40 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Liver, spleen
Species	: Rat
NOAEL	: 150 mg/kg
Application Route	: Oral
Exposure time	: 26 Weeks
Remarks	: No significant adverse effects were reported
Species	: Monkey
NOAEL	: 100 mg/kg
LOAEL	: 200 - 250 mg/kg
Application Route	: Oral
Exposure time	: 39 Weeks
Target Organs	: Kidney
Species	: Rat
NOAEL	: 60 mg/kg
LOAEL	: 180 mg/kg
Exposure time	: 13 Weeks
Target Organs	: Testis, Blood, Liver, spleen, Immune system

## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

Species	: Monkey
NOAEL	: 30 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 4 Weeks
Target Organs	: Blood

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Letermovir:

Ingestion	: Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Oedema, Rash, muscle pain
-----------	---

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

#### Letermovir:

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): 16 mg/l Exposure time: 96 h  EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 8,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility  NOEC (Pseudokirchneriella subcapitata (green algae)): 8,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	: EC50 : > 972 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209  NOEC : 29,6 mg/l

## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 1 mg/l  
 Exposure time: 32 d  
 Species: Pimephales promelas (fathead minnow)  
 Method: OECD Test Guideline 210  
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 1,2 mg/l  
 Exposure time: 21 d  
 Species: Daphnia magna (Water flea)  
 Method: OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

##### Letermovir:

Biodegradability : Result: rapidly degradable  
 Biodegradation: 50 %  
 Exposure time: 6,7 d

### 12.3 Bioaccumulative potential

#### Components:

##### Letermovir:

Partition coefficient: n-octanol/water : log Pow: 2,29

### 12.4 Mobility in soil

#### Components:

##### Letermovir:

Distribution among environmental compartments : log Koc: 3,46

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

**Letermovir Liquid Formulation**

Version 1.20      Revision Date: 30.09.2023      SDS Number: 66869-00021      Date of last issue: 04.04.2023  
Date of first issue: 27.02.2015

---

levels of 0.1% or higher.

---

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

- Product : Dispose of in accordance with local regulations.  
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.
- 

**SECTION 14: Transport information****14.1 UN number**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.2 UN proper shipping name**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.3 Transport hazard class(es)**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.4 Packing group**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good

## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

**IATA (Cargo)** : Not regulated as a dangerous good

**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

### Full text of other abbreviations

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good La-

**Letermovir Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
1.20	30.09.2023	66869-00021	Date of first issue: 27.02.2015

---

boratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN